Shots:

• The companies collaborated to evaluate the safety, tumor shrinkage, clinical activity & immune biomarkers of Galecto’s GB1211 (galectin-3 inhibitor) + Roche’s Tecentriq (PD-L1 checkpoint inhibitor) in P-IIa trial in a ratio (1:1) in 70 patients with NSCLC. The P-IIa study is expected to start in 2022 & results are expected in mid-2023
• Galecto will be the sponsor of the study & retains all rights to GB1211 while Roche will provide clinical supply of Tecentriq
• In multiple preclinical models, GB1211 showed an anti-cancer effect & antifibrotic activity, was well-tolerated & had dose-dependent PK. Additionally, GB1211 is designed to treat multiple cancer and fibrotic diseases

  Ref: PR Newswire | Image: Roche